Per Franklin Nielsen

This inventor holds 6 USPTO granted patents and 2 published patent applications, plus 1 CIPO patent and 3 EPO patents. Top assignee: Novo Nordisk A/s. Active years: 1998-2012.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Per Franklin Nielsen. Retrieved from https://idiyas.com/inventor/per-franklin-nielsen

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 6 (Patent Applications = 2)

% Patents Active = 83.3

CIPO Patents = 1

EPO Patents = 3 (Patent Applications = 1)

Average Co-Inventor Count = 4.5

ph-index = 5

Forward Citations = 609(Granted Patents)

Location History:

Vrl.o slashed.se, DK (1998)
Værløse, DK (2001 - 2007)
Værlose, DK (2007)
Vaerlose, DK (2012)

Company Filing History:

6 out of 1,802

Novo Nordisk A/s

patents

Years Active: 1998-2012

Loading Chart...

6 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 8097698 - Derivatives of GLP-1 analogs (2012-01-17),

2. 7235627 - Derivatives of GLP-1 analogs (2007-06-26),

3. 7226990 - Extendin derivatives (2007-06-05),

4. 6458924 - Derivatives of GLP-1 analogs (2002-10-01),

5. 6268343 - Derivatives of GLP-1 analogs (2001-07-31),

6. 5783416 - Human spasmolytic polypeptide in glycosylated form (1998-07-21),

Title: The Innovations of Per Franklin Nielsen

Introduction: Per Franklin Nielsen, an accomplished inventor based in Vaerlose, Denmark, has made significant contributions to the field of pharmaceuticals. With a remarkable portfolio of six patents, he has dedicated his career to the development of innovative drug formulations.

Latest Patents: Among his notable patents, two focus on the advancements in Glucagon-Like Peptide-1 (GLP-1) analogs. The inventions relate to pharmaceutical compositions that comprise a GLP-1 derivative featuring a lipophilic substituent and a surfactant. These innovations are crucial in enhancing the efficacy and stability of GLP-1 medications.

Career Highlights: Per Franklin Nielsen is currently employed at Novo Nordisk A/S, a leading global healthcare company specializing in diabetes care and other chronic conditions. His contributions to the company and the pharmaceutical industry have underscored his status as a valuable innovator.

Collaborations: Throughout his career, Per has collaborated with talented individuals, including colleagues Per Olaf Huusfeldt and Liselotte Bjerre Knudsen. Their collective expertise in pharmaceuticals has fostered an environment ripe for innovation and development.

Conclusion: Per Franklin Nielsen’s dedication to advancing pharmaceutical innovations has positioned him as an influential figure in the field. His latest patents pave the way for improved treatments, showcasing the importance of continuous research and collaboration in driving medical advancements.

Profile summary based on public USPTO records.